Arrowstreet Capital’s Genomic Health, Inc. GHDX Stock Holding History

Arrowstreet Capital’s Portfolio GHDX Stock Details GHDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-23,475	Closed	-$1.64M	–	1898
2019 Q1	$1.64M	Sell	23,475 -11,964	-34%	-$887K	﹤0.01%	1167
2018 Q4	$2.28M	Buy	+35,439	New	+$2.48M	0.01%	754
2015 Q3	–	Sell	-36,812	Closed	-$1.02M	–	1565
2015 Q2	$1.02M	Buy	+36,812	New	+$1.04M	0.01%	810
2014 Q3	–	Sell	-18,807	Closed	-$515K	–	1187
2014 Q2	$515K	Sell	18,807 -20,882	-53%	-$556K	﹤0.01%	821
2014 Q1	$1.04M	Sell	39,689 -37,269	-48%	-$1.07M	0.01%	819
2013 Q4	$2.25M	Buy	76,958 +41,937	+120%	+$1.33M	0.01%	633
2013 Q3	$1.07M	Buy	35,021 +17,906	+105%	+$599K	0.01%	654
2013 Q2	$543K	Buy	+17,115	New	+$562K	﹤0.01%	625

Other funds holding GHDX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Arrowstreet Capital's GHDX Position: Q2 2019 in Review

Arrowstreet Capital sold out of Genomic Health, Inc. (GHDX) in Q2 2019, closing a stake of 23,475 shares — an estimated $1.64M sold.

Arrowstreet Capital first reported a position in GHDX in Q2 2013 and held it in 8 quarters. The position peaked at $2.28M in Q4 2018. 215 funds tracked by Wall St. Rank hold GHDX as of Q2 2019.

Arrowstreet Capital reported no remaining Genomic Health, Inc. position as of Q2 2019 after selling out during the quarter.
Arrowstreet Capital sold 23,475 Genomic Health, Inc. shares in Q2 2019, an estimated $1.64M.
Arrowstreet Capital first reported a position in Genomic Health, Inc. in Q2 2013 and held it in 8 quarters.
Arrowstreet Capital's Genomic Health, Inc. position peaked at $2.28M in Q4 2018.
215 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q2 2019.

Based on Arrowstreet Capital's 13F filing for Q2 2019, filed 14 Aug 2019.